ISPMD 2022 symposium: The shifting treatment landscape for pediatric movement disorders: Investigational gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency
View our symposium presented at ISPMD 2022, held in Barcelona, Spain, which discusses the potential role of an investigational gene therapy treatment in the management of AADC deficiency
The unmet needs of patients with AADC deficiency, an underdiagnosed and underreported neurometabolic condition, are highlighted
Investigational gene therapy as a potential new treatment option for patients with AADC deficiency is discussed
Key practical details around the management of patients with AADC deficiency in clinical practice are shared
▼ Eladocagene exuparvovec is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Eladocagene exuparvovec (UpstazaTM) is a gene therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype, currently licensed in the European Member States, Great Britain, Iceland, Liechtenstein, Northern Ireland and Norway.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any product.
This is a symposium organized and funded by PTC Therapeutics at the 2022 7th ISPMD in Barcelona, Spain.
This symposium recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200015 | December 2023
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | October 2023
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.